Hierarchical model improves drug recommendations for rheumatoid arthritis patients, suggesting a more tailored approach to treatment.
Rheumatoid arthritis (RA) is an incurable chronic disease with low remission and response rates, making effective drug selection essential. We developed a hierarchical drug recommendation system enhanced by a graph embedding module. By integrating patient feature representations predicted through model probabilities with graph embeddings from EHR and DDI matrices processed by a dual-layer Graph Convolutional Network(GCN), the model predicts drug classes and further refines predictions with subclass information. Using data collected from 352 hospitals across China between 2000 and 2023, we established a cohort of 4975 single-diagnosis RA patients who met the remission criteria. Eight subcategories from four first-line RA drug classes, including glucocorticoids, immunosuppressants, specialized immunosuppressants, and NSAIDs, were selected as recommendation labels. Our model outperforms existing methods, improving F1 and AUC scores by 9% and 19%, respectively, and demonstrates strong potential for personalizing RA medication recommendations.
No takes yet. Share an insight, caveat, or question.
Ouyang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: